James B. Yu Appointed Associate Chief Medical Officer for Radiation Oncology at Smilow Cancer Hospital

Article

In Partnership With:

James B. Yu, MD, MHS, has been promoted to Associate Chief Medical Officer for Radiation Oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network.

James B. Yu, MD, MHS

James B. Yu, MD, MHS, has been promoted to Associate Chief Medical Officer for Radiation Oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network. Yu's clinical leadership in radiation oncology and dedication on behalf of physicians, nurses, caregivers, and patients has led to streamlined radiation treatment, patient care, and innovations in delivery for patients. Yu will continue to ensure multidisciplinary care is expanded throughout the Smilow Cancer Hospital Network as we enter Smilow Cancer Hospital’s second decade of cancer care.

A Professor of Therapeutic Radiology at Yale School of Medicine and Smilow Cancer Hospital, Yu specializes in treating genitourinary cancers, including kidney, bladder, prostate, and central nervous system cancers and cases requiring Gamma Knife stereotactic radiosurgery. In addition, Yu is a member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale. Through his work in COPPER, Yu's research centers on the comparative effectiveness of new radiation technologies and how these new technologies are adopted nationally.

Yu is a two-time winner of Yale Cancer Center’s Cancer Prevention and Control Research Prize, both 2013 and in 2017. He is a graduate of Yale University with both his bachelor’s degree and a masters in health science degree and received his medical degree from the University of Michigan Medical School before completing his residency at Yale New Haven Hospital and serving as Chief Resident.

Related Videos
Sunil Iyer, MD
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Amin Nassar, MD
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Daniel Petrylak, MD
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma